Spyre Therapeutics (NASDAQ:SYRE) and BioStem Technologies (OTCMKTS:BSEM) Critical Comparison

Spyre Therapeutics (NASDAQ:SYRE) and BioStem Technologies (OTCMKTS:BSEM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Analyst Recommendations

This is a summary of current recommendations for Spyre Therapeutics and BioStem Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	0	10	2	3.00
BioStem Technologies	0	1	0	1	3.00

Spyre Therapeutics presently has a consensus price target of $90.25, indicating a potential upside of 22.79%. BioStem Technologies has a consensus price target of $9.00, indicating a potential upside of 117.39%. Given BioStem Technologies’ higher possible upside, analysts clearly believe BioStem Technologies is more favorable than Spyre Therapeutics.

Institutional & Insider Ownership

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Spyre Therapeutics has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, BioStem Technologies has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Profitability

This table compares Spyre Therapeutics and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
BioStem Technologies	N/A	N/A	N/A

Earnings & Valuation

This table compares Spyre Therapeutics and BioStem Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	7,171.62	-$155.20 million	($2.08)	-35.34
BioStem Technologies	$47.48 million	1.48	-$18.85 million	($1.11)	-3.73

BioStem Technologies has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

BioStem Technologies beats Spyre Therapeutics on 7 of the 13 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.